Cara Therapeutics Inc. (CARA) 13.64 $CARA
Cara Therapeutics Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:08PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2014.
Cara Therapeutics to Announce First Quarter 2014 Financial Results on May 12, 2014
GlobeNewswire - Mon May 05, 3:40PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Monday, May 12, 2014, at 4:30 p.m. ET to report first quarter 2014 financial results and provide a corporate update.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.
'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Feb 05, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $11.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
Cara Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Fri Jan 31, 6:00AM CST
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. In addition, Cara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on January 31, 2014 under the ticker symbol "CARA." The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Cara Therapeutics Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:08PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2014.
Cara Therapeutics to Announce First Quarter 2014 Financial Results on May 12, 2014
GlobeNewswire - Mon May 05, 3:40PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Monday, May 12, 2014, at 4:30 p.m. ET to report first quarter 2014 financial results and provide a corporate update.
Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.
'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Feb 05, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $11.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.
IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.
Cara Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Fri Jan 31, 6:00AM CST
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. In addition, Cara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on January 31, 2014 under the ticker symbol "CARA." The offering is expected to close on February 5, 2014, subject to customary closing conditions.
